Journal of Nuclear Cardiology

, Volume 23, Issue 6, pp 1304–1314 | Cite as

Apparent left ventricular cavity dilatation during PET/CT in hypertrophic cardiomyopathy: Clinical predictors and potential mechanisms

  • Paco E. BravoEmail author
  • Abdel Tahari
  • Iraklis Pozios
  • Hong-Chang Luo
  • Frank M. Bengel
  • Richard L. Wahl
  • M. Roselle Abraham
  • Theodore P. Abraham
Original Article



Apparent left ventricular cavity dilatation (LVCD) in patients with hypertrophic cardiomyopathy (HCM) is an incompletely understood phenomenon. We aimed at investigating its clinical predictors and potential mechanisms.


Sixty one HCM patients underwent N-13-ammonia PET for visual evaluation of LVCD, transient ischemic dilatation (TID) index, myocardial blood flow (MBF), coronary flow reserve (CFR), and regional myocardial perfusion (rMP). TID index was also derived at 2–4 and 15–20 minutes.


Visual LVCD and quantitative TID (>1.13 abnormal) agreement were excellent (k 0.91; P < .0001). LVCD-positive (n = 32) patients had greater LV thickness (2.26 ± 0.59 vs 1.92 ± 0.41 cm; P = .005), but lower stress MBF (1.66 ± 0.42 vs 2.07 ± 0.46 mL/minute/g; P < .0001), and CFR (1.90 ± 0.46 vs 2.46 ± 0.69; P < .0001) than LVCD-negative (n = 29) patients. Abnormal rMP was present in 31/32 LVCD-positive but only 12/29 (P < .0001) LVCD-negative. TID index was higher at 2–4 (1.30 ± 0.13) than at 15–20 minutes (1.27 ± 0.12; P = .001) in LVCD-positive, whereas it was the same (1.04 ± 0.07 vs 1.04 ± 0.07; P = .9) in LVCD-negative. In multivariate analysis, global peak MBF, abnormal rMP, and LV thickness were the best predictors of LVCD.


Apparent LVCD is a common finding in HCM, intimately related to abnormal myocardial perfusion, globally impaired vasodilator flow reserve, and degree of hypertrophy. In addition to regional and/or diffuse subendocardial ischemia, some degree of true LV chamber dilatation may also contribute to the occurrence of apparent LVCD in HCM.


PET TID apparent LV cavity dilatation HCM myocardial ischemia 



Hypertrophic cardiomyopathy


Left ventricular cavity dilatation


Myocardial blood flow


Coronary flow reserve


Transient ischemic dilatation


Papillary muscles



The authors declare that they have no conflict of interest.


  1. 1.
    Bravo PE, Pinheiro A, Higuchi T, Rischpler C, Merrill J, Santaularia-Tomas M, et al. PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy. J Nucl Med 2012;53:407-14.CrossRefPubMedGoogle Scholar
  2. 2.
    Weiss AT, Berman DS, Lew AS, Nielsen J, Potkin B, Swan HJ, et al. Transient ischemic dilation of the left ventricle on stress thallium-201 scintigraphy: A marker of severe and extensive coronary artery disease. J Am Coll Cardiol 1987;9:752-9.CrossRefPubMedGoogle Scholar
  3. 3.
    Iskandrian AS, Heo J, Nguyen T, Lyons E, Paugh E. Left ventricular dilatation and pulmonary thallium uptake after single-photon emission computer tomography using thallium-201 during adenosine-induced coronary hyperemia. Am J Cardiol 1990;66:807-11.CrossRefPubMedGoogle Scholar
  4. 4.
    Rischpler C, Higuchi T, Fukushima K, Javadi MS, Merrill J, Nekolla SG, et al. Transient ischemic dilation ratio in 82Rb PET myocardial perfusion imaging: Normal values and significance as a diagnostic and prognostic marker. J Nucl Med 2012;53:723-30.CrossRefPubMedGoogle Scholar
  5. 5.
    Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;124:2761-96.CrossRefPubMedGoogle Scholar
  6. 6.
    Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.CrossRefPubMedGoogle Scholar
  7. 7.
    Bravo PE, Pozios I, Pinheiro A, Merrill J, Tsui BM, Wahl RL, et al. Comparison and effectiveness of regadenoson versus dipyridamole on stress electrocardiographic changes during positron emission tomography evaluation of patients with hypertrophic cardiomyopathy. Am J Cardiol 2012;110:1033-9.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Rajaram M, Tahari AK, Lee AH, Lodge MA, Tsui B, Nekolla S, et al. Cardiac PET/CT misregistration causes significant changes in estimated myocardial blood flow. J Nucl Med 2013;54:50-4.CrossRefPubMedGoogle Scholar
  9. 9.
    Hutchins GD, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl DE. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol 1990;15:1032-42.CrossRefPubMedGoogle Scholar
  10. 10.
    Bangalore S, Yao SS, Chaudhry FA. Role of angiographic coronary artery collaterals in transient ischemic left ventricular cavity dilatation during stress echocardiography. Clin Cardiol 2006;29:305-10.CrossRefPubMedGoogle Scholar
  11. 11.
    Abidov A, Bax JJ, Hayes SW, Hachamovitch R, Cohen I, Gerlach J, et al. Transient ischemic dilation ratio of the left ventricle is a significant predictor of future cardiac events in patients with otherwise normal myocardial perfusion SPECT. J Am Coll Cardiol 2003;42:1818-25.CrossRefPubMedGoogle Scholar
  12. 12.
    Emmett L, Magee M, Freedman SB, Van der Wall H, Bush V, Trieu J, et al. The role of left ventricular hypertrophy and diabetes in the presence of transient ischemic dilation of the left ventricle on myocardial perfusion SPECT images. J Nucl Med 2005;46:1596-601.PubMedGoogle Scholar
  13. 13.
    Robinson VJ, Corley JH, Marks DS, Eberhardt LW, Eubig C, Burke GJ, et al. Causes of transient dilatation of the left ventricle during myocardial perfusion imaging. Am J Roentgenol 2000;174:1349-52.CrossRefGoogle Scholar
  14. 14.
    Sugihara H, Shiga K, Umamoto I, Harada Y, Katahira T, Nakagawa T, et al. Assessment of transient dilation of the left ventricular cavity in patients with hypertrophic cardiomyopathy by exercise thallium-201 scintigraphy. Kaku Igaku 1990;27:1281-9.PubMedGoogle Scholar
  15. 15.
    Cannon RO 3rd, Dilsizian V, O’Gara PT, Udelson JE, Schenke WH, Quyyumi A, et al. Myocardial metabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation 1991;83:1660-7.CrossRefPubMedGoogle Scholar
  16. 16.
    Tanaka M, Fujiwara H, Onodera T, Wu DJ, Matsuda M, Hamashima Y, et al. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation 1987;75:1130-9.CrossRefPubMedGoogle Scholar
  17. 17.
    Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;8:545-57.CrossRefPubMedGoogle Scholar
  18. 18.
    Krams R, Kofflard MJ, Duncker DJ, Von Birgelen C, Carlier S, Kliffen M, et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation 1998;97:230-3.CrossRefPubMedGoogle Scholar
  19. 19.
    Harrigan CJ, Appelbaum E, Maron BJ, Buros JL, Gibson CM, Lesser JR, et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2008;101:668-73.CrossRefPubMedGoogle Scholar
  20. 20.
    Han Y, Osborn EA, Maron MS, Manning WJ, Yeon SB. Impact of papillary and trabecular muscles on quantitative analyses of cardiac function in hypertrophic cardiomyopathy. J Magn Reson Imaging 2009;30:1197-202.CrossRefPubMedGoogle Scholar
  21. 21.
    Janik M, Cham MD, Ross MI, Wang Y, Codella N, Min JK, et al. Effects of papillary muscles and trabeculae on left ventricular quantification: Increased impact of methodological variability in patients with left ventricular hypertrophy. J Hypertens 2008;26:1677-85.CrossRefPubMedGoogle Scholar
  22. 22.
    Brazier JR, Maloney JV Jr, Buckberg GD. Papillary muscle ischemia with patent coronary arteries. Surgery 1975;78:430-7.PubMedGoogle Scholar
  23. 23.
    Waters BL. Clinical and pathologic factors contributing to acute papillary muscle ischemia. Arch Pathol Lab Med 1990;114:601-4.PubMedGoogle Scholar
  24. 24.
    Brand FR, Brown AL Jr, Berge KG. Histology of papillary muscles of the left ventricle in myocardial infarction. Am Heart J 1969;77:26-32.CrossRefPubMedGoogle Scholar
  25. 25.
    Coma-Canella I, Gamallo C, Onsurbe PM, Jadraque LM. Anatomic findings in acute papillary muscle necrosis. Am Heart J 1989;118:1188-92.CrossRefPubMedGoogle Scholar
  26. 26.
    De Busk RF, Harrison DC. The clinical spectrum of papillary-muscle disease. New Engl J Med 1969;281:1458-67.CrossRefPubMedGoogle Scholar
  27. 27.
    Van Tosh A, Hecht S, Berger M, Roberti R, Luna E, Horowitz SF. Exercise echocardiographic correlates of transient dilatation of the left ventricular cavity on exercise thallium-201 SPECT imaging. Chest 1994;106:1725-9.CrossRefPubMedGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 2015

Authors and Affiliations

  • Paco E. Bravo
    • 1
    • 3
    Email author
  • Abdel Tahari
    • 1
  • Iraklis Pozios
    • 2
  • Hong-Chang Luo
    • 2
  • Frank M. Bengel
    • 4
  • Richard L. Wahl
    • 1
  • M. Roselle Abraham
    • 2
  • Theodore P. Abraham
    • 2
  1. 1.Department of RadiologyJohns Hopkins UniversityBaltimoreUSA
  2. 2.Division of CardiologyJohns Hopkins UniversityBaltimoreUSA
  3. 3.Division of CardiologyUniversity of WashingtonSeattleUSA
  4. 4.Department of Nuclear MedicineHannover Medical SchoolHannoverGermany

Personalised recommendations